The latest price target for AVITA Medical (NASDAQ:RCEL) was reported by TD Cowen on August 19, 2026. The analyst firm set a price target for $14.00 expecting RCEL to rise to within 12 months (a possible 37.93% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for AVITA Medical (NASDAQ:RCEL) was provided by TD Cowen, and AVITA Medical maintained their buy rating.

The last upgrade for AVITA Medical Inc happened on August 7, 2026 when BTIG raised their price target to $7. BTIG previously had a neutral for AVITA Medical Inc.

The last downgrade for AVITA Medical Inc happened on October 17, 2025 when Lake Street changed their price target from $8 to $4 for AVITA Medical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AVITA Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AVITA Medical was filed on August 19, 2026 so you should expect the next rating to be made available sometime around August 19, 2027.

While ratings are subjective and will change, the latest AVITA Medical (RCEL) rating was a maintained with a price target of $12.00 to $14.00. The current price AVITA Medical (RCEL) is trading at is $10.15, which is out of the analyst’s predicted range.